NATURE:SARS-CoV-2的抗体依赖性增强的可能性

2020-07-15 MedSci原创 MedSci原创

疾病的抗体依赖性增强(ADE)的可能性是疫苗和抗体疗法发展过程中的一个普遍关注的问题,因为作为抗体保护基础的机制在理论上有可能放大病毒感染或引发免疫病理。

疾病的抗体依赖性增强(ADE)的可能性是疫苗和抗体疗法发展过程中的一个普遍关注的问题,因为作为抗体保护基础的机制在理论上有可能放大病毒感染或引发免疫病理。

在SARS-CoV-2大流行的这一关键时刻,我们更需要认真回顾与疾病ADE风险相关的观察。

目前,还没有任何临床发现、免疫学测定或生物标志物可以将任何严重的病毒感染与免疫增强型疾病区分开来,无论是通过抗体、T细胞还是宿主内在反应。

体外系统和动物模型并不能预测疾病的ADE风险,部分原因是保护性和潜在有害的抗体介导机制是相同的,设计动物模型取决于了解抗病毒宿主反应如何在人体内变得有害。

我们对此的认知缺乏会带来以下两个方面的影响。首先,我们迫切需要全面的研究来确定对SARS-CoV-2保护性免疫的临床相关性。其次,由于我们无法可靠地预测接种疫苗或用抗体治疗后的疾病ADE,无论什么病毒是致病菌,随着COVID-19疾病免疫干预的推进,对人体安全性的细致分析将是至关重要的。

 

原始出处:

Ann M. Arvin et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2, NATURE (2020).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1937936, encodeId=f365193e9367f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Feb 16 13:25:26 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884455, encodeId=de7a188445570, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Feb 23 15:25:26 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813808, encodeId=3c288138083d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:21:59 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321202, encodeId=25a81321202a3, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Jul 17 04:25:26 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
    2021-02-16 hukaixun
  2. [GetPortalCommentsPageByObjectIdResponse(id=1937936, encodeId=f365193e9367f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Feb 16 13:25:26 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884455, encodeId=de7a188445570, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Feb 23 15:25:26 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813808, encodeId=3c288138083d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:21:59 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321202, encodeId=25a81321202a3, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Jul 17 04:25:26 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
    2021-02-23 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1937936, encodeId=f365193e9367f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Feb 16 13:25:26 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884455, encodeId=de7a188445570, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Feb 23 15:25:26 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813808, encodeId=3c288138083d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:21:59 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321202, encodeId=25a81321202a3, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Jul 17 04:25:26 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1937936, encodeId=f365193e9367f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Feb 16 13:25:26 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884455, encodeId=de7a188445570, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Feb 23 15:25:26 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813808, encodeId=3c288138083d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:21:59 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321202, encodeId=25a81321202a3, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Jul 17 04:25:26 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
    2020-07-17 小刀医生

相关资讯

厄瓜多尔白虾包装检出新冠病毒,进口食品还能吃吗?权威解答来了

7月10日下午15时,国务院联防联控机制定召开新闻发布会,商务部、国家卫健委、海关总署和市场监管总局有关负责同志出席新闻发布会,介绍防范疫情输入风险、加强进口冷链食品监管有关信息。

CELL:我国研究人员开发出新冠候选疫苗,并可量产

BBIBP-CorV表现出高效的生产力和良好的遗传稳定性,可用于疫苗生产。这些结果支持在临床试验中进一步评估BBIBP-CorV。

NAT MED:中国大规模新冠抗体流行数据发布

我国研究人员评估了在2020年3月9日至2020年4月10日期间,在中国武汉市和全国各地理区域的宿主血清反应。

SCIENCE:秦川团队发现SARS-CoV-2感染过的猕猴对二次感染有抵抗力

2019年冠状病毒病(COVID-19)是由冠状病毒2型(SARS-CoV-2)感染引起的严重急性呼吸道综合征,现已成为全球流行病。人们目前仍不清楚治愈的患者是否有再感染的风险。

冠状病毒与心血管系统:短期和长期影响

近期,《European Heart Journal》刊登了一篇文章,聚焦冠状病毒对心血管系统的短期和长期影响,除Covid-19外,文章同时回顾了SARS和MERS的心血管影响。